Liver disease blood marker study for people with stiff livers
Part of Digestive system clinical trials.
This study looks at whether certain micro-RNA levels in your blood can help predict how your chronic liver disease is progressing. It is for people who already have some liver stiffness (measured by a special ultrasound) and are being treated at the University Hospital St. Pölten.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had a liver disease for more than six months.
- You need a recent liver stiffness measurement (a type of ultrasound) of 10 kPa or more.
- You must receive care at the Internal Medicine Department of University Hospital St. Pölten.
- You cannot be pregnant.
- You cannot have liver cancer that has spread into major blood vessels or to other parts of the body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people over 18 who have advanced, long-term liver scarring. It uses specialized measurements of liver stiffness and pressure to confirm eligibility and may help doctors better understand this condition.
This study looks at new, non-invasive methods to predict when chronic liver disease might get worse. It could help you and your doctor catch problems early without needing a biopsy or other invasive procedures.
This study looks at whether measuring spleen stiffness and simple blood tests can predict if the liver will recover in people with decompensated cirrhosis. It may help doctors know which patients can improve with treatment.
This trial uses MR elastography (a special MRI) to measure liver stiffness and check for fibrosis (scarring) without a needle biopsy. It may help guide treatment for chronic hepatitis B.
This study looks at microRNA (tiny molecules in blood) to better understand what’s happening during sudden worsening of cirrhosis. It may help doctors recognize and monitor decompensated cirrhosis more accurately.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
Hear when a new Chronic Liver Disease and Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.